| |
Choosing the right partner to deliver decentralised clinical trials is crucial. ICON has the experience and expertise to overcome the challenges in patient recruitment and retention to deliver study success. Explore ICON's DCT capabilities. .png)
|
|
Today’s Big NewsSep 20, 2023 |
|
Avoid costly manufacturing delays by establishing the identity, purity and quality of your starting materials. Download this comprehensive guide to raw materials testing. Learn more. .png)
|
|
| By Nick Paul Taylor Merck KGaA is spreading its bets on an artificial-intelligence-enabled future for drug discovery, inking similar three-target deals with BenevolentAI and Exscientia. The deals are collectively worth more than $30 million upfront and $1 billion in potential milestones. |
|
|
|
| Virtual Event |  |
|
|
By Gabrielle Masson Fresh Tracks Therapeutics is dissolving after spending months searching for alternatives, with the company’s board unanimously approving a liquidation plan. |
By James Waldron PeptiDream is clearly doing something right. Big Pharmas have been queueing round the block to collaborate on the Japanese biotech’s peptide discovery platform, and, now, long-term partner Genentech is back with $40 million in upfront cash for a fresh licensing agreement. |
Sponsored by Rise to Health Coalition Two leaders supporting the Rise to Health Coalition discuss the need for coordinated and collective action across sectors to advance health equity |
|
80% of new drugs fail because of unsatisfactory ADME/Tox results. Identifying ADME and drug interaction risks early is critical to avoiding unnecessary clinical studies, costs, and delays… Read More >> 
|
|
By Annalee Armstrong Boston, the San Francisco Bay Area and San Diego are once again the top markets for life sciences commercial real estate in the U.S., with plenty of opportunities for growth as biotech readies for a comeback, according to a new report. |
By Helen Floersh Astronauts in space lose bone at a rate of about 1% per month on average—twelve times the rate of people on Earth. Researchers sent mice into microgravity to test a new drug. |
By James Waldron Only hours after the Roche unit signed a radiopharmaceutical-focused pact with longtime collaborator PeptiDream, it’s now handed over $47 million to enter the molecular glue space. |
By Max Bayer Nadir Mahmood is taking his first CEO gig leading Rezo Therapeutics, which spun out of UCSF and is chaired by longtime biotech exec George Scangos. |
By Annalee Armstrong NightHawk Biosciences, a biotech that was developing medical countermeasures to defend against emerging biothreats, is officially dropping R&D and sending associated staff out the door to fully focus on its CDMO wing. |
By Nick Paul Taylor Astellas has turned down the chance to option an asset from Taysha Gene Therapies. And with Taysha identifying study design feasibility challenges after talking with the FDA, the biotech has stopped internal development of the candidate and added it to a large pile of dropped and deprioritized programs. |
By Max Bayer After flunking two phase 3 trials, Relmada has turned over the open-label card for its depression med providing the first bit of optimism in months, if not years, for the central-nervous-system-focused biotech. |
By Kevin Dunleavy Early this summer, Novo Nordisk filed multiple lawsuits accusing companies of producing and selling compounded versions of Ozempic and Wegovy. Now, Eli Lilly has done the same, filing eight separate complaints in five states. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
|---|
|
|
|
October 16-18, 2023 | Boston, MA Brought to you by the editors behind Fierce Biotech, this conference is a unique venue where biotech executives can network and learn how to improve their partnership and pipeline strategies. It’s the only event that covers the entire pharma R&D spectrum, from basic research through clinical trials. Countdown is on! Register today to save $200 
|
|
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Whitepaper Learn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper 15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| |
|
